Verseon Gain US Patent Protection for Compounds that Could Eliminate Bleeding Risks of Current Anticoagulants“They could radically improve the standard of care for several hundred million underserved patients around the world,” says Verseon’s CSO David KitaFremont, Calif.— Verseon is pleased.